Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from December 14, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on March 14, 2026.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$100.30 Published $110.33 Target $115.61 Window close $125.14 Peak
$99.00 – $101.25Entry zone — fair-value band
$100.30Published — price the day we called it
$110.33Target — the price the thesis aimed for
$125.14Peak — highest point inside the window, not a realized return
$115.61Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 24 days.

Peak price
$125.14
peak on February 25, 2026 — not a realized return
Peak gain
+24.8%
peak, from the publication price
Window close
$115.61
end-of-window price, context only
Days to target
24
Window
December 14, 2025 – March 14, 2026

The thesis — published December 14, 2025

Predicted growth
+10%
over the measurement window
Target price
$110.33
the price the thesis aimed for
Entry zone
$99.00 – $101.25
the fair-value band we waited for
Price at publication
$100.30
published December 14, 2025
Confidence
68%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck looks like a short-term buying opportunity, not a long-term rethink. A bigger $0.85 dividend in January and news about the growing women's healthcare market have pushed attention higher. Because market enthusiasm is stronger than Merck's business strength, treat this as a short swing trade: buy near support, take profits on rallies, and cut quickly if $100 fails.

Primary drivers

  • Higher dividend may attract income-focused buyers soon
  • Price has been pushed down enough to make a quick rebound likely
  • Pharma is seen as safer when markets get rough, helping demand
  • Big gap between hype and business strength means take profits quickly

How it played out

MRK: target reached in 24 days

Lyra published MRK at $100.30 on 2025-12-14 as a short-term setup with 10% expected growth. The thesis pointed to a higher dividend, a price pushed down enough for a quick rebound, safer pharma demand when markets got rough, and a gap between hype and business strength that made quick profit-taking part of the plan.

Inside the window, MRK reached the $110.33 target in 24 days. It kept rising to a $125.14 peak on 2026-02-25, a 24.8% gain from publication. The signal ended at $115.61 on 2026-03-14, still above the target. The published thesis played out.

What happened during the window

On 2026-02-03, MarketWatch reported that Merck had fourth-quarter 2025 revenue of $16.4 billion, up 5%, and adjusted earnings per share of $2.04. It also reported 2026 revenue guidance of $65.5 billion to $67.0 billion and adjusted earnings guidance of $5.00 to $5.15.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.